Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.79B |
| 2 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$576M |
| 3 |
Microsoft
MSFT
|
+$546M |
| 4 |
iShares MSCI EAFE ETF
EFA
|
+$436M |
| 5 |
JPMorgan Chase
JPM
|
+$324M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$2.48B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.73B |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$765M |
| 4 |
Apple
AAPL
|
+$656M |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$526M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 90.23% |
| 2 | Technology | 2.7% |
| 3 | Consumer Discretionary | 1.66% |
| 4 | Financials | 1.18% |
| 5 | Communication Services | 1.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HEPA
10501
DELISTED
Hepion Pharmaceuticals
HEPA
| $154K | ﹤0.01% |
293
+138
| +89% | +$84.7K |
|
10502
Aquestive Therapeutics
AQST
$630M
| $154K | ﹤0.01% |
93,199
-23,073
| -20% | -$41.7K |
|
10503
PUT
Sasol
SSL
$7.58B
| $154K | ﹤0.01% |
12,400
-7,000
| -36% | -$90.2K |
|
|
FFNW
10504
DELISTED
First Financial Northwest, Inc
FFNW
| $153K | ﹤0.01% |
13,498
-4,849
| -26% | -$53.4K |
|
10505
Antero Midstream
AM
$10.6B
| $153K | ﹤0.01% |
13,166
-12,040
| -48% | -$128K |
|
|
NGM
10506
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $152K | ﹤0.01% |
58,841
-7,582
| -11% | -$27K |
|
|
SBDS
10507
PUT
DELISTED
Solo Brands Inc
SBDS
| $152K | ﹤0.01% |
673
+250
| +59% | +$62.1K |
|
10508
PUT
Gevo
GEVO
$413M
| $152K | ﹤0.01% |
100,100
+18,200
| +22% | +$23.5K |
|
10509
CALL
McEwen Inc
MUX
$1.25B
| $152K | ﹤0.01% |
21,100
-180,100
| -90% | -$1.45M |
|
10510
PUT
Archrock
AROC
$5.48B
| $152K | ﹤0.01% |
14,800
-3,000
| -17% | -$29.6K |
|
10511
CALL
Celularity
CELU
$45.7M
| $152K | ﹤0.01% |
28,590
| – | – |
|
10512
PUT
Fate Therapeutics
FATE
$291M
| $151K | ﹤0.01% |
31,800
+21,500
| +209% | +$119K |
|
10513
CALL
Summit Therapeutics
SMMT
$11B
| $151K | ﹤0.01% |
60,300
-101,700
| -63% | -$186K |
|
10514
Anixa Biosciences
ANIX
$118M
| $151K | ﹤0.01% |
47,258
-108,526
| -70% | -$418K |
|
|
FNUC
10515
Frontier Nuclear and Minerals Inc
FNUC
$54.2M
| $151K | ﹤0.01% |
5,057
+4,027
| +391% | +$127K |
|
|
DSM
10516
BNY Mellon Strategic Municipal Bond Fund
DSM
$288M
| $151K | ﹤0.01% |
+26,477
| New | +$151K |
|
10517
Relmada Therapeutics
RLMD
$462M
| $151K | ﹤0.01% |
61,302
-16,812
| -22% | -$46.5K |
|
10518
PUT
Gray Television
GTN
$497M
| $151K | ﹤0.01% |
+19,100
| New | +$147K |
|
10519
ProShares UltraShort Consumer Staples
SZK
$8.99M
| $150K | ﹤0.01% |
+5,214
| New | +$149K |
|
10520
PUT
OmniAb
OABI
$650M
| $150K | ﹤0.01% |
+29,900
| New | +$121K |
|
|
ACRE
10521
Ares Commercial Real Estate
ACRE
$258M
| $150K | ﹤0.01% |
14,804
-43,050
| -74% | -$393K |
|
|
VLD
10522
PUT
DELISTED
Velo3D, Inc.
VLD
| $150K | ﹤0.01% |
1,986
-694
| -26% | -$48.4K |
|
10523
Inspired Entertainment
INSE
$156M
| $150K | ﹤0.01% |
10,203
-9,423
| -48% | -$128K |
|
10524
Kayne Anderson Energy Infrastructure Fund
KYN
$2.51B
| $150K | ﹤0.01% |
18,426
-37,281
| -67% | -$307K |
|
10525
PUT
Geospace Technologies
GEOS
$68.3M
| $150K | ﹤0.01% |
+19,300
| New | +$153K |
|
Similar funds
Jeff Yass's Q2 2023 Portfolio in Review
As of Q2 2023, Jeff Yass held 13,811 positions worth $492B, up 4.6% from $470B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Jeff Yass's Q2 2023 filing shows 1,371 new, 4,862 increased, 5,559 reduced and 1,866 closed positions. Its largest new stake was State Street SPDR Portfolio Aggregate Bond ETF: 1,297,445 shares worth $32.9M. The largest sale was Invesco QQQ Trust, an estimated $2.48B.
By sector, the portfolio is most concentrated in Miscellaneous at 90% of assets, down from 90% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jeff Yass's largest Q2 2023 buy was State Street SPDR Portfolio Aggregate Bond ETF: 1,297,445 shares worth $32.9M.
- Jeff Yass added most to NVIDIA in Q2 2023, an estimated $1.79B increase.
- Jeff Yass's biggest Q2 2023 reduction was Invesco QQQ Trust, cutting an estimated $2.48B.
- Jeff Yass fully exited Vanguard Intermediate-Term Corporate Bond ETF in Q2 2023, selling an estimated $45.5M.
- Jeff Yass's ten largest holdings make up 30% of its $492B portfolio in Q2 2023.
- Jeff Yass opened 1,371 new positions and closed 1,866 in Q2 2023.
- Jeff Yass's portfolio value rose 4.6% quarter-over-quarter to $492B.
Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.